Kyverna Therapeutics (KYTX) Cash from Financing Activities (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Cash from Financing Activities data on file, last reported at -$101000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 75.6% year-over-year to -$101000.0; the trailing twelve-month figure through Mar 2026 stood at $141.5 million (up 10580.07% YoY), and the FY2025 full-year result was $141.2 million, down 58.12% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$101000.0, down from $140.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $338.0 million in Q1 2024 and bottomed at -$1.4 million in Q4 2023.
• The 4-year median for Cash from Financing Activities is -$144000.0 (2023), against an average of $41.3 million.
• Peak annual rise in Cash from Financing Activities reached 234856.25% in 2024, while the deepest fall reached 102.28% in 2024.
• A 4-year view of Cash from Financing Activities shows it stood at -$1.4 million in 2023, then soared by 85.01% to -$215000.0 in 2024, then jumped by 65561.86% to $140.7 million in 2025, then slumped by 100.07% to -$101000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$101000.0 (Q1 2026), $140.7 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.

Peer Comparison